<DOC>
	<DOCNO>NCT01857583</DOCNO>
	<brief_summary>To assess safety pharmacokinetics DU-176b administer patient severe renal impairment undergo orthopedic surgery lower limb , compare DU-176b administer patient mild renal impairment ( MiRI ) undergo orthopedic surgery low limb . For reference , safety DU-176b patient SRI undergo orthopedic surgery lower limb compare fondaparinux .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study DU-176b Administered Patients With Severe Renal Impairment Undergoing Orthopedic Surgery The Lower Limbs</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients SRI MiRI undergo orthopedic surgery lower limb Patients hemodialysis schedule undergo hemodialysis study period Patients significantly high risk bleed thromboembolism Patients receive another antithrombotic therapy unable suspend therapy Patients evidence hepatic function test abnormality</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>orthopedic surgery lower limb</keyword>
	<keyword>severe renal impairment</keyword>
</DOC>